



June 3, 2009

## **MannKind to Present at the Needham Life Sciences Conference**

VALENCIA, Calif.--(BUSINESS WIRE)--Jun. 3, 2009-- **MannKind Corporation (Nasdaq: MNKD)**, focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the 8<sup>th</sup> Annual Needham Life Sciences Conference on Wednesday, June 10, 2009 at 10:00 AM (EDT) at The New York Palace Hotel in New York City.

Interested parties can access a link to the live webcast of the presentation from the News & Events section of the Company's website at <http://www.mannkindcorp.com>. Replays of the presentations will be available for 14 days.

### **About MannKind Corporation**

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its diabetes pipeline includes AFRESA®, which has completed phase 3 clinical trials, and MKC253, which is currently in phase 1 clinical trials. MannKind has submitted an NDA to the FDA requesting approval of AFRESA for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. MannKind maintains a website at <http://www.mannkindcorp.com> to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.

Source: MannKind Corporation

### **MannKind Corporation**

Matthew J. Pfeffer  
Corporate Vice President and  
Chief Financial Officer  
661-775-5300  
[mpfeffer@mannkindcorp.com](mailto:mpfeffer@mannkindcorp.com)